UUnited States Read More Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update04.08.2025 Syndax Pharmaceuticals, Inc. – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – –…